Occurrence Policy

An occurrence policy is a type of insurance policy that provides coverage for claims that arise from incidents or events that occur during the policy period, regardless of when the claims are actually made. This means that even if a claim is made years after the policy has expired, if the incident occurred during the policy period, it would still be covered.

An example of an occurrence policy is a liability insurance policy for a construction company. If someone is injured on a construction site during the policy period, the occurrence policy would provide coverage for any resulting claims, even if they are made after the policy has expired.

Key features of an occurrence policy may include:

• Coverage for claims that arise from incidents or events that occur during the policy period, regardless of when the claims are made

• Generally higher premiums than claims-made policies due to the longer period of coverage

• Coverage that continues even after the policy has expired, as long as the incident occurred during the policy period

• No need for extended reporting or tail coverage, as the policy covers claims as long as they arise from incidents during the policy period

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.